Canada's Valeant gains from new deals, raises 2013 outlook

By Krithika Krishnamurthy and Rod Nickel (Reuters) - Valeant Pharmaceuticals International Inc , Canada's biggest publicly traded drugmaker, raised its full-year adjusted earnings forecast for the second time and reported a quarterly profit, boosted by sales from its skin-care acquisitions. The company has aggressively pursued acquisitions since its 2010 takeover by Biovail Corp, which assumed the Valeant name. Valeant bought contact lens maker Bausch & Lomb Holdings Inc for $8.7 billion in the second quarter. ...



via Health News Headlines - Yahoo! News http://news.yahoo.com/valeant-sees-smaller-deals-discussing-merger-equals-132424442.html